Applications of liposomal drug delivery systems to cancer therapy

Nanotechnology for Cancer Therapy

Volumn , Issue , 2006, Pages 595-611

  Gabizon, Alberto A ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551712780     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (88)

1. Gabizon, A. A., Pegylated liposomal doxorubicin: Metamorphosis of an old drug into anew form of chemotherapy, Cancer Invest., 19(4), 424-436, 2001.
2. Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P. et al., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, J. Clin. Oncol., 23(31), 7794-7803, 2005.
3. Lasic, D. D. and Papahadjopoulos, D., Medical Applications of Liposomes, Elsevier, Amsterdam, 1998.
4. Barenholz, Y., Relevancy of drug loading to liposomal formulation therapeutic efficacy, J. Liposome Res., 13(1), 1-8, 2003.
5. Moghimi, S. M., Hunter, A. C., and Murray, J. C., Nanomedicine: Current status and future prospects, FASEB J., 19(3), 311-330, 2005.
6. Hanahan, D. and Weinberg, R. A., The hallmarks of cancer, Cell, 100(1), 57-70, 2000.
7. Van Den Bossche, B. and Van de Wiele, C., Receptor imaging in oncology by means of nuclear medicine: Current status, J. Clin. Oncol., 22(17), 3593-3607, 2004.
8. Kastan, M. B., Molecular biology of cancer: The cell cycle, In Cancer: Principles &Practice of Oncology, DeVita, V. T., Hellman, S., and Rosenberg, S. A., Eds., 5th ed., Lippincott-Raven, Philadelphia, pp. 121-134, 1997.
9. Jain, R. K., Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function, J. Control. Release, 74(1-3), 7-25, 2001.
10. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K. et al., Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl Acad. Sci. USA, 88(24), 11460-11464, 1991.
11. Gabizon, A. and Martin, F., Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours, Drwgs, 54(Suppl. 4), 15-21, 1997.
12. Swabb, E. A., Wei, J., and Gullino, P. M., Diffusion and convection in normal and neoplastic tissues, Cancer Res., 34(10), 2814-2822, 1974.
13. Harrington, K. J., Rowlinson-Busza, G., Syrigos, K. N., Abra, R. M., Uster, P. S., Peters, A. M. et al., Influence of tumour size on uptake of ln-DTPA-labelled pegylated liposomes in ahuman tumour xenograft model, Br. J. Cancer, 83(5), 684-688, 2000.
14. Safra, T., Groshen, S., Jeffers, S., Tsao-Wei, D. D., Zhou, L., Muderspach, L. et al., Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: Analysis of toxicities and predictors of outcome, Cancer, 91(1), 90-100, 2001.
15. Gabizon, A., Tzemach, D., Mak, L., Bronstein, M., and Horowitz, A. T., Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models, J. Drug Target, 10(7), 539-548, 2002.
16. Gregoriadis, G., Leathwood, P. D., and Ryman, B. E., Enzyme entrapment in liposomes, FEBS Lett., 14(2), 95-99, 1971.
17. Allen, T. M. and Chonn, A., Large unilamellar liposomes with low uptake into the reticuloendothelial system, FEBS Lett., 223(1), 42-16, 1987.
18. Gabizon, A. and Papahadjopoulos, D., Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, Proc. Natl Acad. Sci. USA, 85(18), 6949-6953, 1988.
19. Allen, T. M., Austin, G. A., Chonn, A., Lin, L., and Lee, K. C., Uptake of liposomes by cultured mouse bone marrow macrophages: Influence of liposome composition and size, Biochim. Biophys. Acta, 1061(1), 56-64, 1991.
20. Woodle, M. C. and Lasic, D. D., Sterically stabilized liposomes, Biochim. Biophys. Acta, 1113(2), 171-199, 1992.
21. Klibanov, A. L., Maruyama, K., Torchilin, V. P., and Huang, L., Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett., 268(1), 235-237, 1990.
22. Allen, T. M., Hansen, C., Martin, F., Redemann, C., and Yau-Young, A., Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo, Biochim. Biophys. Acta, 1066(1), 29-36, 1991.
23. Lasic, D. D. and Martin, F. J., Stealth Liposomes, CRC Press, Boca Raton, FL, 1995.
24. Huang, S. K., Lee, K. D., Hong, K., Friend, D. S., and Papahadjopoulos, D., Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice, Cancer Res., 52(19), 5135-5143, 1992.
25. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., and Jain, R. K., Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in ahuman tumor xenograft, Cancer Res., 54(13), 3352-3356, 1994.
26. Gabizon, A. A., Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes, Cancer Res., 52(4), 891-896, 1992.
27. Bally, M. B., Masin, D., Nayar, R., Cullis, P. R., and Mayer, L. D., Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice, Cancer Chemother. Pharmacol., 34(2), 137-146, 1994.
28. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting, Adv. Enzyme Regul., 41, 189-207, 2001.
29. Goren, D., Horowitz, A. T., Zalipsky, S., Woodle, M. C., Yarden, Y., and Gabizon, A., Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies, Br. J. Cancer, 74(11), 1749-1756, 1996.
30. Gabizon, A., Shmeeda, H., Horowitz, A. T., and Zalipsky, S., Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates, Adv. Drug Deliv. Rev., 56(8), 1177-1192, 2004.
31. Stohrer, M., Boucher, Y., Stangassinger, M., and Jain, R. K., Oncotic pressure in solid tumors is elevated, Cancer Res., 60(15), 4251-4255, 2000.
32. Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D., Peters, A. M., Vile, R. G. et al., Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin. Cancer Res., 7(2), 243-254, 2001.
33. Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E. et al., Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86(1), 72-78, 1999.
34. Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M. et al., Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacoki-netics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma, J. Clin. Pharmacol., 36(1), 55-63, 1996.
35. Young, R. C., Ozols, R. F., and Myers, C. E., The anthracycline antineoplastic drugs, N. Engl. J. Med., 305(3), 139-153, 1981.
36. Forssen, E. A. and Tokes, Z. A., In vitro and in vivo studies with adriamycin liposomes, Biochem. Biophys. Res. Commun., 91(4), 1295-1301, 1979.
37. Gabizon, A. A., Liposomal anthracyclines, Hematol. Oncol. Clin. North Am., 8(2), 431-450, 1994.
38. Lasic, D. D., Frederik, P. M., Stuart, M. C., Barenholz, Y., and McIntosh, T. J., Gelation of liposome interior. Anovel method for drug encapsulation, FEBS Lett., 312(2-3), 255-258, 1992.
39. Haran, G., Cohen, R., Bar, L. K., and Barenholz, Y., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta, 1151(2), 201-215, 1993.
40. Gabizon, A., Shmeeda, H., and Barenholz, Y., Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies, Clin. Pharmacokinet., 42(5), 419-436, 2003.
41. Colbern, G. T., Hiller, A. J., Musterer, R. S. et al., Significant increase in antitumor potency of doxorubicin HCI by its encapsulation in pegylated liposomes, J. Liposome Res., 9, 523-538, 1999.
42. Ewer, M. S., Martin, F. J., Henderson, C., Shapiro, C. L., Benjamin, R. S., and Gabizon, A. A., Cardiac safety of liposomal anthracyclines, Semin. Oncol., 31(6 Suppl. 13), 161-181, 2004.
43. Allen, T. M. and Martin, F. J., Advantages of liposomal delivery systems for anthracyclines, Semin. Oncol., 31(6 Suppl. 13), 5-15, 2004.
44. Vail, D. M., Amantea, M. A., Colbern, G. T., Martin, F. J., Hilger, R. A., and Working, P. K., Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmaco-kinetic studies, Semin. Oncol., 31(6 Suppl. 13), 16-35, 2004.
45. Henderson, C. I., Established and emerging roles of liposomal anthracyclines in oncology. Introduction, Semin.. Oncol., 31(6 Suppl. 13), 1-4, 2004.
46. Rifkin, R. M., Gregory, S. A., Mohrbacher, A., and Hussein, M. A., PEGylated liposomal doxoru-bicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma, Cancer, 106(4), 848-858, 2006.
47. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R. et al., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res., 54(4), 987-992, 1994.
48. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z. et al., Liposomal doxor-ubicin: Antitumor activity and unique toxicities during two complementary phase Istudies, J. Clin. Oncol., 13(7), 1777-1785, 1995.
49. Alberts, D. S., Muggia, F. M., Carmichael, J., Winer, E. P., Jahanzeb, M., Venook, A. P. et al., Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials, Semin. Oncol., 31(6 Suppl. 13), 53-90, 2004.
50. Huang, S. K., Martin, F. J., Jay, G., Vogel, J., Papahadjopoulos, D., and Friend, D. S., Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene, Am. J. Pathol., 143(1), 10-14, 1993.
51. Krown, S. E., Northfelt, D. W., Osoba, D., and Stewart, J. S., Use of liposomal anthracyclines in Kaposi's sarcoma, Semin. Oncol., 31(6 Suppl. 13), 36-52, 2004.
52. 2, Ann. Oncol., 11(8), 1029-1033, 2000.
53. Berry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B. et al., The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegy-lated liposomal doxorubicin, Ann. Oncol., 9(7), 711-716, 1998.
54. Gabizon, A. A., Lyass, O., Berry, G. J., and Wildgust, M., Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies, Cancer Invest., 22(5), 663-669, 2004.
55. O'Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A. et al., Reduced cardio-toxicity and comparable efficacy in aphase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann. Oncol., 15(3), 440-449, 2004.
56. Kehrer, D. F., Bos, A. M., Verweij, J., Groen, H. J., Loos, W. J., Sparreboom, A. et al., Phase Iand pharmacologic study of liposomal lurtotecan, NX 211: Urinary excretion predicts hematologic toxicity, J. Clin. Oncol., 20(5), 1222-1231, 2002.
57. Gelmon, K. A., Tolcher, A., Diab, A. R., Bally, M. B., Embree, L., Hudon, N. et al., Phase Istudy of liposomal vincristine, J. Clin. Oncol., 17(2), 697-705, 1999.
58. Soepenberg, O., Sparreboom, A., de Jonge, M. J., Planting, A. S., de Heus, G., Loos, W. J. et al., Realtime pharmacokinetics guiding clinical decisions; phase Istudy of aweekly schedule of liposome encapsulated paclitaxel in patients with solid tumours, Eur. J. Cancer, 40(5), 681-688, 2004.
59. Boulikas, T., Stathopoulos, G. P., Volakakis, N., and Vougiouka, M., Systemic lipoplatin infusion results in preferential tumor uptake in human studies, Anticancer Res., 25(4), 3031-3039, 2005.
60. Gabizon, A., Tzemach, D., Horowitz, A. T., Shmeeda, H., Yeh, Y., and Zalipsky, S., Reduced toxicity and superior therapeutic activity of aMitomycin Clipid-based prodrug incorporated in Pegylated liposomes. Clin. Cancer Res. 12(6), 1913-1920, 2006.
61. Bandak, S., Goren, D., Horowitz, A., Tzemach, D., and Gabizon, A., Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models, Anticancer Drugs, 10(10), 911-920, 1999.
62. Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G. et al., Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer, Ann. Oncol., 12(4), 493-496, 2001.
63. Meerum Terwogt, J. M., Groenewegen, G., Pluim, D., Maliepaard, M., Tibben, M. M., Huisman, A. et al., Phase Iand pharmacokinetic study of SPI-77, aliposomal encapsulated dosage form of cisplatin, Cancer Chemother. Pharmacol., 49(3), 201-210, 2002.
64. Zamboni, W. C., Gervais, A. C., Egorin, M. J., Schellens, J. H., Zuhowski, E. G., Pluim, D. et al., Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in apreclinical tumor model of melanoma, Cancer Chemother. Pharmacol., 53(4), 329-336, 2004.
65. Mori, A., Kennel, S. J., van Borssum Waalkes, M., Scherphof, G. L., and Huang, L., Characterization of organ-specific immunoliposomes for delivery of 3', 5'-0-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung metastasis model, Cancer Chemother. Pharmacol., 35, 447-456, 1995.
66. Asai, T., Kurohane, K., Shuto, S., Awano, H., Matsuda, A., Tsukada, H. et al., Antitumor activity of 5' - O-dipalmitoylphosphatidyl 2' - C-cyano-2'-deoxy-1-B-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization, Biol. Pharm. Bull., 21(7), 766-771, 1998.
67. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J. et al., Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery, Clin. Cancer Res., 8(4), 1172-1181, 2002.
68. Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D. et al., Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy, Cancer Res., 63(21), 7400-7409, 2003.
69. Allen, T. M., Sapra, P., and Moase, E., Use of the post-insertion method for the formation of ligand-coupled liposomes, Cell Mol. Biol. Lett., 7(3), 889-894, 2002.
70. Gabizon, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., and Zalipsky, S., In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice, Clin. Cancer Res., 9(17), 6551-6559, 2003.
71. Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N. et al., Liposome-encapsulated doxorubicin compared with conventional doxorubicin in arandomized multicenter trial as first-line therapy of metastatic breast carcinoma, Cancer, 94(1), 25-36, 2002.
72. Bomgaars, L., Geyer, J. R., Franklin, J., Dahl, G., Park, J., Winick, N. J. et al., Phase Itrial of intrathecal liposomal cytarabine in children with neoplastic meningitis, J. Clin. Oncol., 22(19), 3916-3921, 2004.
73. Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L. et al., Osteosarcoma: Arandomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate, J. Clin. Oncol., 23(9), 2004-2011, 2005.
74. Hong, R. L. and Tseng, Y. L., Phase Iand pharmacokinetic study of astable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: The relation between pharmacokinetic property and toxicity, Cancer, 91(9), 1826-1833, 2001.
75. O'Byrne, K. J., Thomas, A. L., Sharma, R. A., DeCatris, M., Shields, F., Beare, S. et al., Aphase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer, Br. J. Cancer, 87(1), 15-20, 2002.
76. Lu, C., Perez-Soler, R., Piperdi, B., Walsh, G. L., Swisher, S. G., Smythe, W. R. et al., Phase II study of aliposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma, J. Clin. Oncol., 23(15), 3495-3501, 2005.
77. Ozpolat, B., Lopez-Berestein, G., Adamson, P., Fu, C. J., and Williams, A. H., Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers, J. Pharm. Pharm. Sci., 6(2), 292-301, 2003.
78. Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y. et al., Phase Iand pharmacokinetic study of MCC-465, adoxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer, Ann. Oncol., 15(3), 517-525, 2004.
79. Booser, D. J., Esteva, F. J., Rivera, E., Valero, V., Esparza-Guerra, L., Priebe, W. et al., Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer, Cancer Chemother. Pharmacol., 50(1), 6-8, 2002.
80. Verschraegen, C. F., Gilbert, B. E., Loyer, E., Huaringa, A., Walsh, G., Newman, R. A. et al., Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies, Clin. Cancer Res., 10(7), 2319-2326, 2004.
81. Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulieres, D. et al., Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer, J. Clin. Oncol., 23(27), 6674-6681, 2005.
82. Skubitz, K. M. and Anderson, P. M., Inhalational interleukin-2 liposomes for pulmonary metastases: Aphase Iclinical trial, Anticancer Drugs, 11(7), 555-563, 2000.
83. Rudin, C. M., Marshall, J. L., Huang, C. H., Kindler, H. L., Zhang, C., Kumar, D. et al., Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: Aphase Istudy, Clin. Cancer Res., 10(21), 7244-7251, 2004.
84. Boulikas, T., Low toxicity and anticancer activity of anovel liposomal cisplatin (lipoplatin) in mouse xenografts, Oncol. Rep., 12(1), 3-12, 2004.
85. Dark, G. G., Calvert, A. H., Grimshaw, R., Poole, C., Swenerton, K., Kaye, S. et al., Randomized trial of two intravenous schedules of the topoisomerase Iinhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: Atrial of the national cancer institute of Canada clinical trials group, J. Clin. Oncol., 23(9), 1859-1866, 2005.
86. Yoo, G. H., Hung, M. C., Lopez-Berestein, G., LaFollette, S., Ensley, J. F., Carey, M. et al., Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer, Clin. Cancer Res., 7(5), 1237-1245, 2001.
87. Colbern, G. T., Dykes, D. J., Engbers, C., Musterer, R., Hiller, A., Pegg, E. et al., Encapsulation of the topoisomerase Iinhibitor GL147211C in PEGylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts, Clin. Cancer Res., 4(12), 3077-3082, 1998.
88. Beutel, G., Glen, H., Schoffski, P., Chick, J., Gill, S., Cassidy, J. et al., Phase Istudy of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors, Clin. Cancer Res., 11(15), 5487-5495, 2005.